GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter
Executive Summary
Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.
You may also be interested in...
GSK Sees Light At End Of Shingrix Tunnel As COVID-19 Eases
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
10 Non-COVID News Updates To Listen For In Second Quarter Reporting
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.